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Summary. Incomplete penetrance and variable expressivity
confound the diagnosis and therapy of most inherited throm-
botic and hemorrhagic disorders. For many of these diseases,
some or most of this variability is determined by genetic
modifiers distinct from the primary disease gene itself. Clues
toward identifying such modifier genes may come from
studying rare Mendelian disorders of hemostasis. Examples
include identification of the cause of combined factor V and
VIII deficiency as mutations in the ER Golgi intermediate
compartment proteins LMAN1 and MCFD2. These proteins
form a cargo receptor that facilitates the transport of factors V
and VIII, and presumably other proteins, from the ER to the
Golgi. A similar positional cloning approach identified
ADAMTS-13 as the gene responsible for familial TTP. Along
with the work of many other groups, these findings identified
VWFproteolysis byADAMTS-13 as a key regulatory pathway
for hemostasis. Recent advances in mouse genetics also provide
powerful tools for the identification of novel genes contributing
to hemostatic balance. Genetic studies of inbred mouse lines
with unusually high and unusually low plasma VWF levels
identified polymorphic variation in the expression of a
glycosyltransferase gene, Galgt2, as an important determinant
of plasma VWF levels in the mouse. Ongoing studies in mice
genetically engineered to carry the factor V Leiden mutation
may similarly identify novel genes contributing to thrombosis
risk in humans.
Keywords: coagulation protein disorders, factor V, factor VIII,
hemostasis, genetic model, von Willebrand factor.
Introduction
Hemostasis is a relatively recent evolutionary innovation, first
arising in vertebrates coincident with the appearance of a high
pressure, closed circulatory system [1,2]. The latter introduced
the need for a rapidly responding and tightly regulated
hemostatic system. In an invertebrate, sublethal injury to the
exoskeleton is probably uncommon, and can be repaired with a
slow time course. In contrast, in the setting of the vertebrate
circulatory system, even a minor injury could result in
exsanguination in a matter of minutes, requiring a rapid and
directed response. However, if this response is too robust, the
outcomewould be lethal occlusion of the vascular tree. The end
result of these complex evolutionary forces is the highly
integrated hemostatic system, involving many genes and
interconnected regulatory pathways. A tip of this delicate
balance in the wrong direction can result in pathologic
bleeding, whereas a tilt in the other direction may lead to
pathologic thrombosis.
Perhaps more than any other biologic system, our current
understanding of hemostasis is derived in large part from the
study of human genetic diseases. Genetic deficiencies in nearly
every component of the clotting system have been identified
either in humans, or recently in mice, or both [3,4]. Although
we have a fairly complete catalog of such genetic defects on the
bleeding side of human disease, there are likely to be a number
of genes contributing to thrombotic disorders that remain to be
identified.
Even among the well defined, single gene disorders of
hemostasis and thrombosis, considerable variability remains to
be explained. Patients with such an inherited bleeding or
thrombotic disease presumably carry a mutation in a major
known disease gene. Although this mutation may be the
primary cause of the disease, the clinical manifestations are
often still highly variable. For many genetic diseases, not
everyone inheriting the disease-causing mutation manifests
clinical symptoms, a phenomenon referred to by geneticists as
incomplete penetrance. For example, in families with typical
autosomal dominant type 1 von Willebrand disease (VWD),
penetrance is generally incomplete (50% or lower) [5]. In
addition, among those individuals in the VWD family who do
express bleeding symptoms, the severity of this bleeding can
also be highly variable, a phenomenon referred to as variable
expressivity.
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What are the causes for incomplete penetrance and variable
expressivity? These factors are illustrated in Fig. 1. For most
inherited bleeding and thrombotic disorders, there are obvious
environmental factors that can alter disease severity. For
example, age, gender, prior surgery and trauma are all major
risk factors for thrombosis and bleeding. Finally, we must
consider the actions of other genes that may modify the effect
of the primary disease causing mutation [6]. It is the identity of
these modifier genes that is the major focus of this review and a
primary goal of our laboratory’s research program. This
problem resembles the prominent challenge to the field of
human genetics of uncovering the genes contributing to
complex, multi-gene disorders such as hypertension, diabetes,
and cardiovascular disease [7].
The most direct approach to identify modifier genes is to
study genetic linkage or association in large collections of
human families or populations. These strategies have been
applied to a number of complex human disorders with only
limited success to date [7]. This manuscript will discuss two
other approaches. The first is based on the hypothesis that clues
toward identifying common modifier genes may come from
studying rare Mendelian disorders of hemostasis. The second
group of studies takes advantage of the power of mouse
genetics. It is our hope that genes identified through genetic
studies in the mouse, as well as studies of rare Mendelian
disorders, may provide candidates to later be tested directly in
humans through whole genome linkage and association
studies.
Clues from rare Mendelian hemostatic disorders
The power of human genetics, particularly bolstered by the
dramatic recent advances provided by the human genome
project, nowmake it possible in principle to directly identify the
underlying gene for nearly any simple, single gene disorder. The
rate-limiting step is usually the identification of sufficient
human genetic material in the form of well characterized
families and pedigrees.
Combined deficiency of factor V and factor VIII
An example of this approach comes from the study of a rare
inherited bleeding disorder, combined deficiency of factor V
and factor VIII (F5F8D). These patients exhibit a remark-
able coordinate reduction in the plasma level of clotting
factors V and VIII. Although originally suspected to be due
to deficiency of protein C inhibitor [8], this explanation was
later disproved [9] and the cause of this disorder remained a
mystery until a direct genetic approach became possible, as a
result of the human genome project. It is remarkable to note
that F5F8D patients exhibit very similar reductions in both
factor V and factor VIII, generally to the range of
approximately 10% of normal, despite expression of these
two proteins in different tissues and to markedly different
levels (plasma levels of factor V are approximately 100-fold
higher than those of factor VIII). The key to this puzzle that
made a genetic approach possible was the pioneering work of
Seligsohn et al. [10], who, along with other groups, had
carefully characterized these families. Using a genetic
approach called homozygosity mapping to study these
pedigrees, we were able to map the gene responsible for
F5F8D in most families to the long arm of chromosome 9
[11], subsequently confirmed by another group [12]. Further
genetic studies eventually identified the responsible gene as
ERGIC53, now referred to as LMAN1 [13]. This protein was
previously identified as a marker of the intermediate com-
partment between the ER and Golgi, although of unknown
function. The identification of mutations in LMAN1 as a
cause of F5F8D suggested that this gene plays a unique role
in the transport of proteins between the ER and Golgi.
However, mutations in LMAN1 only explain about three-
fourth of patients with F5F8D, with the remaining subgroup
demonstrating normal levels of LMAN1 and no mutations in
the LMAN1 gene [14,15]. This observation led to further
genetic analysis in the remaining subgroup of patients, with
identification of the responsible gene as MCFD2 [16].
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Fig. 1. Factors affecting severity of inherited bleeding and thrombotic diseases.
1562 D. Ginsburg
 2005 International Society on Thrombosis and Haemostasis
nearly all patients with F5F8D. MCFD2 is an approximately
16 kDa protein that is retained within the intermediate
compartment between the ER and Golgi via its interaction
with LMAN1. These two proteins form a complex that
appears to serve as cargo-receptor for the selective facilitated
transport of a specific subset of secreted proteins, including
factor V and factor VIII. These findings are a striking
example of how studies of human disease can provide basic
insight into fundamental biologic problems. In addition, this
work identifies a novel biologic pathway that impacts on
hemostatic balance and is a potential source of modifier gene
effects for hemostatic diseases. One could imagine that
polymorphic variation within components of this system
could affect factor V and factor VIII levels and thereby alter
bleeding or thrombotic risk. This hypothesis remains to be
tested.
ADAMTS-13 and TTP
Using a similar positional cloning strategy, we recently
identified ADAMTS-13 as the gene responsible for familial
TTP [17]. This approach was again based on the study of
rare patients with this inherited disorder. Independently,
three other groups identified the same protein as the von
Willebrand factor (VWF) cleaving protease by purification of
this activity from plasma, followed by protein sequence
analysis [18–20]. These findings identified a new pathway for
the regulation of VWF and platelet function and a new
candidate for a genetic modifier potentially affecting overall
hemostatic balance and the risk of bleeding and/or throm-
bosis. A number of common polymorphisms in the AD-
AMTS-13 gene have been identified [17], including a very
common mutation in the Japanese population resulting in
partial loss of function [21]. These polymorphisms are thus
candidates to modify the risk for a variety of thrombotic and
vascular diseases, although this hypothesis also remains to be
tested.
Genetic approaches in the mouse
Our laboratory is taking two complementary approaches in
the laboratory mouse in an effort to identify novel genetic
loci, which may serve as modifiers of hemostatic balance in
humans and thus, as modifier genes for inherited bleeding
and clotting diseases. Recent advances in mouse and human
genetics have provided powerful new tools to address
complex genetic disorders and to identify modifier genes
[6]. Our first approach focuses on a mouse model for the
most common inherited bleeding disorder in humans, VWD.
The second approach centers on a mouse model for the most
common inherited genetic risk factor for thrombosis in
human, factor V Leiden.
It is important to note that these two approaches could
potentially be quite complementary. That is genes that modify
plasma VWF levels, in addition to altering risk for bleeding in
VWD patients and hemophilics, might also alter thrombotic
risk in patients with thrombophilia mutations. Similarly,
mutations identified in the factor V Leiden screen could also
alter the balance in a clinically significant way in patients with
inherited bleeding disorders. Indeed, factor V Leiden has
already been identified as a potential modifier of bleeding
severity in hemophilia [22,23].
Identifying modifier genes for VWF in the mouse
To study genetic factors that could potentially modify the
penetrance and expressivity of VWD, we are focusing on the
control of plasma VWF levels in the mouse. VWF level is
known to have a large genetic component in humans, with
heritability estimates ranging from60–70% from twin studies
[24] to as low as 25% from linkage studies in large pedigrees
[25,26]. ABO blood group is known to be a major genetic
modifier of plasma VWF level and is perhaps one of the best
defined examples of a human modifier gene. Individuals with
blood type O, generally have VWF levels that are 25%–30%
lower than individuals with any of the non-O blood types [27].
ABO blood group appears to account for approximately 30%
of the genetic variation in VWF level [24,28] with the modifier
genes responsible for the remaining 70% still to be identified. In
addition to being important determinants of incomplete
penetrance and variable expressivity in VWD and hemophilia,
variation in VWF level, with its secondary effect on FVIII, may
also represent an important risk factor for thrombosis. Recent
studies suggest that elevated VWF levels may account for as
much as 16%of the attributable risk for thrombosis (compared






















































Fig. 2. Variation in plasmaVWF level among inbredmouse strains. VWF
levels were determined by ELISA as previously described [30,31,33].
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A survey of a number of different inbred mouse strains
demonstrates a wide variation in the level of plasma VWF, as
shown in Fig. 2. This variation is at least as large as that
observed in human populations, where VWF levels can vary
over as much as fivefold (50%–250%). In previous work, we
have taken advantage of the relatively high levels of plasma
VWF in several wild-derived mouse strains, including CASA/
Rk and PWK/Ph [30,31]. The levels of VWF in these mice are
five- to 10-fold higher than in C57BL/6J and up to 20-fold
higher than in the mouse strain RIIIS/J. The latter strain had
been originally reported by Sweeney et al. [32] as amousemodel
for type 1 VWD, with a VWF level of approximately 50%
compared with C57BL/6J. We previously mapped the major
gene responsible for low plasma VWF in the RIIIS/J strain
to mouse chromosome 11 [30], defining the corresponding
locus as Mvwf (for modifier of VWF). Subsequent positional
cloning efforts [33] identified Mvwf as a mutation in the
glycosyltransferase gene, Galgt2. The remarkable molecular
mechanism underlyingMvwf was shown to be a tissue-specific
switch inGalgt2 expression pattern. In the C57BL/6J strain and
most other inbred mice, VWF expression is restricted to the GI
epithelial cell. However, in RIIIS/J and related strains, Galgt2
expression is turned off in the epithelium and turned on in the
entire endothelial cell vascular bed.As the endothelial cell is also
the site of VWF protein expression, the result of GALGT2 and
VWF expression in the same cell is a subtle alteration in the
carbohydrate structure on VWF, which leads to rapidly
accelerated clearance [33].
These findings suggest that polymorphic variation in carbo-
hydrate processing could be an important general mechanism
for the genetic modification of plasma levels for a whole host of
plasma proteins, including a number of clotting factors. Genes
involved in the synthesis or processing of glycoconjugates are
estimated to comprise up to 1% of the human genome and
many are highly polymorphic [34]. One obvious example of
such polymorphic variation can be found in the glycosyltransf-
erases responsible for the ABO blood group polymorphism in
humans. Indeed, the ABO structure is known to be present on
plasma VWF [35] and it is likely that the effect of ABO blood
type on plasma VWF level results from a very similar
mechanism to that identified for the Mvwf mutation in mice.
Specifically, there is evidence to suggest that the type ABO
sugar structures on VWF may subtly alter VWF clearance,
accounting for the reduced levels in individuals with blood type
O [36]. Recent studies in our laboratory demonstrate that a
number of other inbred mouse strains carry this same Mvwf
mutation, presumably derived from a common founder allele
in the mouse population. Current efforts are also focused on
identifying the specific DNA sequence change on the Mvwf
allele responsible for this remarkable switch in tissue-specific
gene transcription program.
Using a similar approach, we have now performed genetic
crosses for several other mouse strains and in preliminary
studies havemapped at least three other genes within themouse
genome that appear to modify plasma VWF levels. It is our
hope that the identification of these genes may uncover other
important candidates as potential modifiers of plasma VWF
level in humans.
Whole genome ENU mutagenesis to screen for modifiers
of factor V Leiden
Factor V Leiden was discovered through direct genetic
studies in humans [37], beginning with the pioneering work
of Dahlbäck and co-workers [38,39], who identified APC
resistance and demonstrated that it is an autosomal domin-
ant trait. Subsequent work by a number of groups succeeded
in identifying a single nucleotide change resulting in the
amino acid substitution R506Q in factor V as the most
common known genetic predisposition to thrombosis in
humans [40]. The factor V Leiden mutation appears to have
arisen as a single mutation event in human evolutionary
history, dated approximately 20 000–30 000 years ago [41].
This mutation is generally only found in Europe and the
USA, where the population prevalence ranges from 2% to
10%. Despite several studies suggesting detrimental effects of
factor V Leiden, including the obvious known increase in
thrombosis predisposition, its high allele frequency suggests
at least some form of balancing positive selection. A recent
report from Kerlin et al. [42] found a surprising resistance of
factor V Leiden mice (described below) to endotoxin-induced
mortality. Extrapolating these results to humans, they also
demonstrated a remarkable protection from sepsis-related
mortality in humans carrying factor V Leiden. These findings
suggest that the positive selection for factor V Leiden in
humans may lie in protection from a specific infectious
pathogen.
In order to study genetic factors modifying factor V
Leiden thrombosis predisposition, we generated a mouse
model by a knock-in of the factor V Leiden mutation into
the endogenous factor V gene at the orthologous amino acid
position (R504Q). The resulting mice exhibit a mild pro-
thrombotic predisposition, very similar to the human
phenotype [43]. A rare, spontaneous thrombus was observed
in heterozygous mice, while homozygous mice showed a
more severe thrombosis, which was variably affected by
mouse genetic background. The factor V Leiden mouse also
provides a valuable tool for testing interactions with other
clotting factor mutations. Genetic cross of the factor V
Leiden mice with mice carrying a knockout in the protein Z
gene showed a surprising synthetic lethal interaction [44].
Protein Z-deficient mice exhibit normal survival, as do factor
V Leiden mice. However, mice carrying both defects showed
a uniformly lethal thrombotic phenotype early in life. These
findings provided the first direct evidence for the function of
protein Z as a regulator of hemostasis.
Similarly, a dramatic synthetic lethal interaction was
observed in mice carrying a knockout of the tissue factor
pathway inhibitor gene (TFPI) [45]. Although complete
deficiency of TFPI in the mouse results in an early embryonic
lethality [46], mice heterozygous for the TFPI knockout allele
that are expressing 50% of the normal level of TFPI, exhibit
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normal survival. Again, a remarkable synthetic lethal pheno-
type was observed between mice carrying the factor V Leiden
mutation and those carrying the TFPI mutation [45]. The key
genetic cross is shown in Fig. 3. Mice homozygous for the
factor V Leiden mutation are essentially normal, as are mice
that are doubly heterozygous for the factor V Leiden mutation
(FVQ/+) and the TFPI mutation (Tfpi+/)). In the bottom
part of the figure, the four possible genotypes in the offspring
from this cross are seen, with the expected Mendelian
frequencies of 25% for each genotype. To our surprise, only
a rare mouse survived to weaning carrying a combination of
FVQ/Q and Tfpi+/), whereas close to expected numbers were
observed for all other genotypes. These data demonstrate a
synthetic lethal interaction between these two genetic defects.
This result was elegantly predicted in vitro by van’t Veer et al.
[47], whose work provides a biochemical explanation for the
in vivo interaction between factor V Leiden and TFPI. These
authors observed in an in vitro clotting assay a marked increase
in the dependence of thrombin generation on TFPI concen-
tration when factor V Leiden was substituted for wild-type
factor V. Thus, our findings in genetically engineered mice
represent a satisfying in vivo confirmation of these in vitro
predictions.
We are currently using this observation as the basis for a
large-scale genetic screening experiment in the mouse, as
depicted in Fig. 4. For this study, the same genetic cross as
shown in Fig. 3 is performed, with the introduction of random
mutations by the chemical agent ENU (N-ethyl-N-nitroso-
urea). Random chemical mutagenesis has been used widely as






































Fig. 3. A cross between mice carrying the factor V Leiden mutation and a knockout in the Tfpi gene (adapted from data in Ref. [45]).
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applied by a number of groups to screen for specific mutations
in the experimental mouse. Such genetic screens can theoret-
ically detect a mutation in any gene, limited only by the
ingenuity of the screening approach. One of the early successes
of this method was the isolation of the first mammalian clock
gene by screening of mutagenized mice for alterations in
circadian rhythm [48].
Unfortunately, no highly sensitive and specific and yet rapid
and inexpensive test is currently available to screen for
thrombosis predisposition or bleeding in the mouse (or in
humans for that matter). The key innovation in our approach
is to use a specific sensitized genetic background for the
mutagenesis study, rather than performing it in wild-type mice.
A similar approach was recently used for genes affecting
thrombopoiesis [49]. Our sensitized genetic background takes
advantage of the synthetic lethal phenotype described in Fig. 3.
In this screen, the same genetic cross is performed, but now
with the introduction of random mutations throughout the
genome, looking for mice that survive the lethal genetic
combination as a result of one of these introduced mutations.
Thus, this sensitized suppressor screen looks for genemutations
that suppress the lethal synthetic phenotype.
ENU treatment using standard protocols is estimated to
produce multiple mutations, resulting in the disruption of, on
average, 30–50 different genes in each sperm produced by the
ENU-treated male [50]. The G1 offspring mice from this cross
will thus carry an inactivated copy for 30–50 genes, with a
normal copy from the mother. The screen is designed as a
dominant screen and will only detect those mutations where a
loss of only one of two copies of the gene results in a sufficient
tip in the hemostatic balance to rescue the lethal thrombotic
phenotype. It is these very mutations that we hypothesize will
identify the genes of greatest interest as potential candidates for
thrombosis modifiers in humans. Common polymorphisms
within these genes in the human population may by themselves
have little effect, but when combined with a primary pro-
thrombotic or hemorrhagic disease mutation, could result in a
major shift in overall hemostatic balance. In preliminary
studies, a number of such candidate suppressor gene mutations
have been identified and current efforts are focused on
mapping and eventually positionally cloning these genes. The
mutations identified in this way may provide important insight
into the overall regulation of hemostasis balance, as well as
identifying key candidates to test as modifier genes in humans.
What classes and types of genes might we anticipate to
identify in this way? First, we expect that we may identify
known clotting factors for which the overall level of expression
is particularly critical, such as variation in TFPI level in the
setting of factor V Leiden, as described above. Again, these
genes would be key candidates to explore as potential modifier
genes in humans. A second class of genes might involve
regulators of pathways entirely outside of our conventional
view of hemostasis. Examples here would include the ER to
Golgi transport pathway identified through the studies of
F5F8D or the metalloprotease ADAMTS-13 identified
through genetic studies of TTP. Any such novel pathways
would provide new areas for biologic investigation, as well as
novel potential targets for anticoagulant drug development and
new candidates for genetic modifier genes in humans.
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